Home › Kanser sa Thyroid › Pennsylvania
Pag-aaral pangklinika para sa Kanser sa Thyroid sa Pennsylvania
7 pag-aaral para sa Kanser sa Thyroid ang naghahanap ng mga kalahok sa mga site sa Pennsylvania.
Mga Lungsod sa Pennsylvania
Opisyal na teksto ng pag-aaral (English)
DESTINY-PANTUMOUR04
- Research Site, Philadelphia
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07124000Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- at 7 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05334069Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
- Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitPhase 2
Edad 2 hanggang 25 · Lahat ng kasarian · Na-update Hul 24, 2026 · NCT06458036Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitPhase 2
Edad 2 hanggang 99 · Lahat ng kasarian · Na-update Nob 14, 2025 · NCT05783323APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Penn State Milton S. Hershey Medical Center, Hershey
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 27, 2025 · NCT03175224Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery
- Thomas Jefferson University, Philadelphia
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2025 · NCT06918223Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
- Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Dis 12, 2024 · NCT05668962Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.